APOE gene polymorphisms and diabetic peripheral neuropathy

Archives of Medical Science

Volumn 8, Issue 4, 2012, Pages 583-588

  Monastiriotis, Christodoulos ^a   Papanas, Nikolaos ^a   Veletza, Stavroula ^a   Maltezos, Efstratios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Apolipoprotein E; Diabetes mellitus; Diabetic neuropathy; Polymorphisms

Indexed keywords

APOLIPOPROTEIN E;

ALLELE; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; EMBASE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR;

EID: 84866868532     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.30279     Document Type: Review

References (46)

1. Thomas PK. Metabolic neuropathy. J R Coll Phys Lond 1973; 7: 154-60.
2. Shaw JE, Simmet PZ, Gries FA, Ziegler D. Epidemiology of diabetic neuropathy. In: Gries FA, Cameron NE, Low PA, Ziegler D (eds). Textbook of diabetic neuropathy. Stuttgart/New York: Thieme 2003; 64-82.
3. Sima AA. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003; 60: 2445-64. (Pubitemid 37487263)
4. Várkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab 2008; 10: 99-108.
5. Yagihashi S, Mizukami H, Sugimoto K. Mechanism of diabetic neuropathy: where are we now and where to go? J Diabetes Investigation 2011; 2: 18-32.
6. Malik RA. Current and future strategies for the management of diabetic neuropathy. Treat Endocrinol 2003; 2: 389-400. (Pubitemid 37462238)
7. Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol 2011; 7: 682-90.
8. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001; 24: 1448-53. (Pubitemid 33716436)
9. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108-11. (Pubitemid 36070653)
10. Ziegler D, Papanas N, Roden M; GDC Study Group. Neuropad: evaluation of three cut-off points of sudomotor dysfunction for early detection of polyneuropathy in recently diagnosed diabetes. Diabet Med 2011; 28: 1412-5.
11. Sivenius K, Pihlajamaki J, Partanen J, Niskanen L, Laakso M, Uusitupa M. Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes. Diabetes Care 2004; 27: 2021-6. (Pubitemid 38989249)
12. Papanas N, Papatheodorou K, Papazoglou D, Kotsiou S, Christakidis D, Maltezos M. An insertion/deletion polymorphism in the alpha2B adrenoreceptor gene is associated with peripheral neuropathy in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2007; 115: 327-30. (Pubitemid 46877867)
13. Vague P, Dufayet D, Coste T, Moriscot C, Jannot MF, Raccah D. Association of diabetic neuropathy with Na/K ATPase gene polymorphism. Diabetologia 1997; 40: 506-11. (Pubitemid 27186785)
14. Facer P, Casula AM, Smith GD, et al. Differential expression of the capsaicin receptor TRPV I and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurology 2007; 7: 11.
15. Anjaneyulu M, Berent-Spillson A, Russel JW. Metabotropic glutamate receptors (mGluRs) and diabetic neuropathy. Current Drug Targets 2008; 9: 85-93. (Pubitemid 351201683)
16. Jofre-Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res 2008; 52: 131-45. (Pubitemid 351211806)
17. Pitas R, Boyles J, Lee S, Foss D, Mahley R. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 1987; 917: 148-61. (Pubitemid 17231059)
18. Boyles J, Pitas R, Wilson E, Mahley R, Taylor J. Apolipoprotein E associated with astrocytic glia of the central nervous system and with non myelinating glia of the peripheral nervous system. J Clin Invest 1985; 76: 1501-13. (Pubitemid 16193568)
19. Bedlack RS, Strittmatter WJ, Morgenlander JC. Apolipoprotein E and neuromuscular disease: a critical review of literature. Arch Neurol 2000; 57: 1561-5.
20. Strittmatter W, Saunders A, Schmechel D, Pericak- Vance M, Enghild J, Roses A. Apolipoprotein E: high-avidity binding to b-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 1977-81. (Pubitemid 23069980)
21. Strittmatter W, Roses A. Apolipoprotein E and Alzheimer's disease. Proc Natl Acad Sci USA 1995; 92: 4725-7.
22. Corder E, Saunders A, Strittmatter W, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. Science 1993; 261: 921-3. (Pubitemid 23275809)
23. Corder E, Saunders A, Risch N, et al. Protective effect of apolipoprotein E type 2 allele for late-onset Alzheimer disease. Nat Genet 1994; 7: 180-4. (Pubitemid 24174658)
24. Tsuzuki S, Murano T, Watanabe H, Itoh Y, Miyashita Y, Shirai K. The examination of apoE phenotypes in diabetic patients with peripheral neuropathy. Rinsho Byori 1998; 46: 829-33.
25. Alberts M, Graffagnino C, McClenny C, et al. APOE genotype and survival from intracerebral haemorrhage. Lancet 1995; 346: 575.
26. Teasdale G, Nicoll J, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997; 350: 1069-71. (Pubitemid 27437858)
27. Jordan B, Relkin N, Ravdin L, Jacobs A, Bennett A, Gandy S. Apolipoprotein E E4 associated with chronic traumatic brain injury in boxing. JAMA 1997; 278: 136-40. (Pubitemid 27287671)
28. Bedlack RS, Edelman D, Gibbs JW 3rd, et al. APOE genotype is a risk factor for neuropathy severity in diabetic patients. Neurology 2003; 60: 1022-4. (Pubitemid 36348941)
29. Apfel SC, Schwartz S, Adornato B, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA 2000; 284: 2215-21.
30. Zhou Z, Hoke A, Cornblath DR, Griffin JW, Polydefkis M. APOE epsilon4 is not a susceptibility gene in idiopathic or diabetic sensory neuropathy. Neurology 2005; 64: 139-41. (Pubitemid 40082953)
31. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995; 45: 1115-21.
32. Voron'ko OE, Yakunina NYu, Strokov IA, Lavrova IN, Nosikov VV. Association of polymorphic markers of the lipid metabolism genes with diabetic neuropathy in type 1 diabetes mellitus. Mol Biology 2005; 39: 206-9. (Pubitemid 40684846)
33. American Diabetes Association and American Academy of Neurology. Report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes 1988; 37: 1000-4.
34. Dyck PJ, Melton JL, O'Brien PC, Service FG. Approaches to improve epidemiological studies of diabetic neuropathy: Insights from the Rochester diabetic neuropathy study. Diabetes 1997; 46 Suppl 2: S5-8. (Pubitemid 27377390)
35. Skene J, Shooter E. Denervated sheath cells secrete a new protein after nerve injury. Proc Natl Acad Sci USA 1983; 80: 4169-73. (Pubitemid 13072787)
36. Gelman B, Rifai N, Goodrum J, Bouldin T, Krigman M. Apolipoprotein E is released by rat sciatic nerve during segmental demyelination and remyelination. J Neuro - pathol Exp Neurol 1987; 46: 644-52. (Pubitemid 18024315)
37. Popko B, Goodrum J, Bouldin T, Zhang S, Maeda N. Nerve regeneration occurs in the absence of apolipoprotein E in mice. J Neurochem 1993; 60: 1155-8. (Pubitemid 23066741)
38. Fullerton S, Strittmatter W, Matthew W. Peripheral sensory nerve defects in apolipoprotein E knockout mice. Exp Neurol 1998; 153: 156-63. (Pubitemid 28452308)
39. Newman M, Croughwell N, Blumenthal J, et al. Predictors of cognitive decline after cardiac operation. Ann Thorac Surg 1995; 59: 1326-30.
40. Tardiff B, Newman M, Saunders A, et al. Preliminary report of a genetic basis for cognitive decline after cardiac operations. Ann Thorac Surg 1997; 64: 715-20. (Pubitemid 27435681)
41. Kolovou G, Kolovou V, Vasiliadis I, Wierzbicki AS, Mikhailidis DP. Ideal lipid profile and genes for an extended life span. Curr Opin Cardiol 2011; 26: 348-55.
42. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-93.
43. Valensi P, Attali JR, Gagant S. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy. Diabet Med 1993; 10: 933-9. (Pubitemid 23359001)
44. Mojaddidi M, Quattrini C, Tavakoli M, Malik RA. Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy. Curr Diab Rep 2005; 5: 417-22. (Pubitemid 43020007)
45. Bissinger A, Grycewicz T, Grabowicz W, Lubinski A. The effect of diabetic autonomic neuropathy on P-wave duration, dispersion and atrial fibrillation. Arch Med Sci 2011; 7: 806-12.
46. Katsiki N, Banach M. Statins and the risk of diabetes: the debate. Arch Intern Med 2012; 172: 895-6.